Key facts
- This page summarizes Richard Anthony Cunningham's Form 4 filing for TYME TECHNOLOGIES, INC..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2022, 18:00.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Disposed to Issuer
Disposed to Issuer
Disposed to Issuer
Additional SEC filing notes
Section 16 status
Richard Anthony Cunningham is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Footnote F1
This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 87,640 shares of Syros common stock for $23.51 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
Footnote F2
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 21,910 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
Footnote F3
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 58,105 shares of Syros common stock for $7.53 per share, after giving effect to the Reverse Split.